Condition

Hormone Receptor Negative Tumor

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 2 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials2
Recruiting2
Common interventions25
Lead sponsors shown2
Advertisement

Common interventions

9MW2821DRUG1ABT-888DRUG1AmcenestrantDRUG1Amcenestrant + AbemaciclibDRUG1Amcenestrant + LetrozoleDRUG1AMG 386 and TrastuzumabDRUG1AMG 386 with or without TrastuzumabDRUG1AMG 479 (Ganitumab) plus MetforminDRUG1AnlotinibDRUG1ApatinibDRUG1ARV-471DRUG1ARV-471 + AbemaciclibDRUG1ARV-471 + LetrozoleDRUG1ARX788DRUG1ARX788 + CemiplimabDRUG1BenmelstobartDRUG1CamrelizumabDRUG1CarboplatinDRUG1CemiplimabDRUG1Cemiplimab plus REGN3767DRUG1CyclophosphamideDRUG1DalpiciclibDRUG1Dan222 + NiraparibDRUG1Datopotamab deruxtecanDRUG1Datopotamab deruxtecan + DurvalumabDRUG1

Trial status mix

RECRUITING2

Phase mix

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.